Background: We reviewed the results of low-calcium hemodialysis (LCHD; 1.25 mmol/L) in the treatment of 42 cases admitting with hypercalcemic crisis. Methods: All patients (≥18 years) who started LCHD due to hypercalcemia between 2002 and 2017 were retrospectively analyzed. Biochemical data were obtained at the beginning of the first hemodialysis and at the end of the last hemodialysis. -“Refractory” cases were defined as patients having albumin corrected serum total calcium (SCatotal) levels above 10.2 mg/dL despite of all medical, surgical, and hemodialysis treatments. Results: By acceptance of 3 cases admitted again over 6 months as new cases, a total of 42 cases (male, 57.1%) with a mean age of 55.9 ± 14.8 years underwent urgent hemodialysis. Most of the patients (82.1%) had malignancies. The mean SCatotal level at the beginning of hemodialysis sessions was 15.89 ± 2.53 mg/dL. The mean decline of SCatotal level was 4.63 ± 2.72 mg/dL. Refractory cases received hemodialysis after admission significantly later than improved cases (48 [interquartile ranges (IQR) 24–168] vs. 24 [IQR 12–48] h, p = 0.010). Serum creatinine and SCatotal levels at the last visit were significantly more in refractory cases than improved cases (1.92 [IQR 0.81–3.41] vs. 1.30 [IQR 0.8–1.7] mg/dL, p = 0.031 and 12.43 ± 2.53 vs. 8.86 ± 0.67 mg/dL, p = 0.000 respectively). Mortality was significantly higher in refractory cases than improved cases (58.8 vs. 10.5%, p = 0.002). Overall mortality rate was 33.3%. Conclusion: Hypercalcemic crisis is a life-threatening condition and should be managed immediately.

Keywords:
Acute kidney injury, Hypercalcemia, Hypercalcemic crisis, Low-calcium hemodialysis, Parathyroid hormone
1.
Ahmad S, Kuraganti G, Steenkamp D: Hypercalcemic crisis: a clinical review. Am J Med 2015; 128: 239–245.
2.
Potts JT Jr, Jüppner H: Disorders of the parathyroid gland and calcium homeostasis; in Longo DL, Fauci AS, Kasper DL, Hauser S (eds): Harrison’s Principles of Internal Medicine. McGraw-Hill, 2012, pp 3096–3120.
3.
Minisola S, Pepe J, Piemonte S, Cipriani C: The diagnosis and management of hypercalcaemia. BMJ 2015; 350:h2723.
4.
Haap M, Tschritter O, Artunc F, Rettig I, Riessen R: Hypercalcemic crisis in intensive care. Dtsch Med Wochenschr 2012; 137: 1100–1104.
5.
Ziegler R: Hypercalcemic crisis. J Am Soc Nephrol 2001; 12:S3–S9.
6.
Stewart AF: Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005; 352: 373–379.
7.
Loh HH, Mohd Noor N: The use of hemodialysis in refractory hypercalcemia secondary to parathyroid carcinoma. Case Rep Crit Care 2014; 2014: 140906.
8.
Mirrakhimov AE: Hypercalcemia of malignancy: an update on pathogenesis and -management. N Am J Med Sci 2015; 7: 483–493.
9.
Bilezikian JP: Management of acute hypercalcemia. N Eng J Med 1992; 326: 1196–1203.
10.
Eisenberg E, Gotch FA: Normocalcemic hyperparathyroidism culminating in hypercalcemic crisis. Treatment with hemodialysis. Arch Intern Med 1968; 122: 258–264.
11.
Strauch BS, Ball MF: Hemodialysis in the treatment of severe hypercalcemia. JAMA 1976; 235: 1347–1348.
12.
Cardella CJ, Birkin BL, Rapoport A: Role of dialysis in the treatment of severe hypercalcemia: report of two cases successfully treated with hemodialysis and review of the literature. Clin Nephrol 1979; 12: 285–290.
13.
Koo WS, Jeon DS, Ahn SJ, Kim YS, Yoon YS, Bang BK: Calcium-free hemodialysis for the management of hypercalcemia. Nephron 1996; 72: 424–428.
14.
Maxwell MH, Rockney RE, Kleeman CR, Twiss MR: Peritoneal dialysis. 1. Technique and applications. J Am Med Assoc 1959; 170: 917–924.
15.
Lemann J Jr, Donatelli AA: Calcium intoxication due to primary hyperparathyroidism. A medical and surgical emergency. Ann Intern Med 1964; 60: 447–461.
16.
Nolph KD, Stoltz M, Maher JF: Calcium free peritoneal dialysis. Treatment of vitamin D intoxication. Arch Intern Med 1971; 128: 809–814.
17.
Raphael JC, Kleinknecht D, Chanard J, Jungers P: Neoplasmic acute hypercalcemia with kidney failure. Possibilities and limitations of treatment by extrarenal purification. Presse Med 1971; 79: 1103–1106.
18.
Leroy J, Robert M, Fillastre JP, Humbert G, Hemet J: Acute hypercaldemic episodes due to parathyroid disorder. Sem Hop 1973; 49: 487–493.
19.
Miach PJ, Dawborn JK, Martin TJ, Moon WJ: Management of the hypercalcaemia of malignancy by peritoneal dialysis. Med J Aust 1975; 1: 782–784.
20.
Heyburn PJ, Selby PL, Peacock M, Sandler LR, Parsons FM: Peritoneal dialysis in the management of severe hypercalcaemia. Br Med J 1980; 280: 525–526.
21.
Hamilton JW, Lasrich M, Hirszel P: Peritoneal dialysis in the treatment of severe hypercalcemia. J Dial 1980; 4: 129–138.
22.
Kleinman GE, Rodriquez H, Good MC, Caudle MR: Hypercalcemic crisis in pregnancy associated with excessive ingestion of calcium carbonate antacid (milk-alkali syndrome): successful treatment with hemodialysis. Obstet Gynecol 1991; 78: 496–499.
23.
Srámek V, Novák I, Matĕjovic M, Rokyta R, Nalos M, Hora P, Pittrová H: Continuous venovenous hemodiafiltration (CVVHDF) with citrate anticoagulation in the treatment of a patient with acute renal failure, hypercalcemia, and thrombocytopenia. Intensive Care Med 1998; 24: 262–264.
24.
Martínez Mateu JG, Losada González GP, Munar Vila MA, Uriol Rivera M, Gómez Marqués G, Tugores AC: Multiple myeloma, severe hypercalcaemia, acute renal failure and multiple organ failure due to calcinosis. Nefrologia 2011; 31: 233–234
25.
Au S, Dunham M, Godinez T: Treatment of medically refractory hypercalcemic crisis. Int J Artif Organs 2012; 35: 538–541.
26.
Chacón A, Vilar A, Arroyo D, Sarró F, Craver L, Ros S, López C, Castillo A, Matías-Guiu X, Fernández-Giráldez E: Acute kidney injury secondary to very severe hypercalcaemic crisis caused by primary hyperparathyroidism. Nefrologia 2015; 35: 224–226.
27.
Rosenbaum JL, Schumacher OP: Hemodialysis in treatment of hypercalcemia. Ohio State Med J 1963; 59: 1208–1209.
28.
Chavez CM: Parathyroid adenoma. South Med J 1970; 63: 1167–1175.
29.
Camus C, Charasse C, Jouannic-Montier I, Seguin P, Tulzo YL, Bouget J, Thomas R: Calcium free hemodialysis: experience in the treatment of 33 patients with severe hypercalcemia. Intensive Care Med 1996; 22: 116–121.
30.
Wang CC, Chen YC, Shiang JC, Lin SH, Chu P, Wu CC: Hypercalcemic crisis successfully treated with prompt calcium-free hemodialysis. Am J Emerg Med 2009; 27: 1174.e1–e3.
31.
Kaiser W, Biesenbach G, Kramar R, Zazgornik J: [Calcium-free hemodialysis – value in therapy of hypercalcemic crisis]. Klin Wochenschr 1989; 67: 86–91.
32.
Hechanova LA, Sadjadi SA: Severe hypercalcemia complicating recovery of acute kidney injury due to rhabdomyolysis. Am J Case Rep 2014; 15: 393–396.
33.
Leehey DJ, Ing TS: Correction of hypercalcemia and hypophosphatemia by hemodialysis using a conventional, calcium-containing dialysis solution enriched with phosphorus. Am J Kidney Dis 1997; 29: 288–290.
34.
Loew H, Wagner H: Value of hemodialysis therapy of hypercalcemic crisis in primary hyperparathyroidism. Verh Dtsch Ges Inn Med 1973; 79: 741–743.
35.
Gradwohl-Matis I, Franzen M, Seelmaier C, Brunauer A, Dankl D, Dünser MW, Salmhofer H: Renal replacement therapy with regional citrate anticoagulation as an effective method to treat hypercalcemic crisis. ASAIO J 2015; 61: 219–223.
36.
Pittaway JF, Srirangalingam U, Hanson PL, Jones P, Drake WM: Renal replacement therapy as a treatment for severe refractory hypercalcemia. Minerva Endocrinol 2014; 39: 231–233.
37.
Kindgen-Milles D, Kram R, Kleinekofort W, Morgera S: Treatment of severe hypercalcemia using continuous renal replacement therapy with regional citrate anticoagulation. ASAIO J 2008; 54: 442–444.
38.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J: CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–612.
39.
KDIGO AKI Work Group: KDIGO clinical practice guideline for acute kidney injury. Kidney Int 2012;(suppl 2): 1–138.
40.
Kooman J, Basci A, Pizzarelli F, Canaud B, Haage P, Fouque D, Konner K, Martin-Malo A, Pedrini L, Tattersall J, Tordoir J, Vennegoor M, Wanner C, ter Wee P, Vanholder R: EBPG guideline on haemodynamic instability. Nephrol Dial Transplant 2007; 22(suppl 2):ii22–ii44.
41.
Gardner EC Jr, Hersh T: Primary hyperparathyroidism and the gastrointestinal tract. South Med J 1981; 74: 197–199.
42.
Kleeman CR: Metabolic coma. Kidney Int 1989; 36: 1142–1158.
43.
Guimard C, Batard E, Lavainne F, Trewick D: Is severe hypercalcemia immediately life-threatening? Eur J Emerg Med 2018; 25: 110–113.
44.
Thosani S, Hu MI: Denosumab: a new agent in the management of hypercalcemia of malignancy. Future Oncol 2015; 11: 2865–2871.
45.
Toussaint N, Cooney P, Kerr PG: Review of dialysate calcium concentration in hemodialysis. Hemodial Int 2006; 10: 326–337.
46.
Maynard JC, Cruz C, Kleerekoper M, Levin NW: Blood pressure response to changes in serum ionized calcium during hemodialysis. Ann Intern Med 1986; 104: 358–361.
47.
Sherman RA, Bialy GB, Gazinski B, Bernholc AS, Eisinger RP: The effect of dialysate calcium levels on blood pressure during hemodialysis. Am J Kidney Dis 1986; 8: 244–247.
48.
Van Kuijk WH, Mulder AW, Peels CH, Harff GA, Leunissen KM: Influence of changes in ionized calcium on cardiovascular reactivity during hemodialysis. Clin Nephrol 1997; 47: 190–196.
49.
Broman M, Carlsson O, Friberg H, Wieslander A, Godaly G: Phosphate-containing dialysis solution prevents hypophosphatemia during continuous renal replacement therapy. Acta Anaesthesiol Scand 2011; 55: 39–45.
50.
Chang JM, Tsai JC, Hwang SJ, Chen HC, Guh JY, Lai YH: Intravenous repletion of phosphorus deficiency in the chronic renal failure patients with severe hypophosphatemia. Kaohsiung J Med Sci 1997; 13: 540–547.
51.
Slomp J, van der Voort PH, Gerritsen RT, Berk JA, Bakker AJ: Albumin-adjusted calcium is not suitable for diagnosis of hyper- and hypocalcemia in the critically ill. Crit Care Med 2003; 31: 1389–1393.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.